Drug Trial Radar · NCT03605862
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Last checked: Nov 20, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,756
Actual
Start
Sep 11, 2018
Primary completion
Feb 4, 2019
Study completion Feb 4, 2019
Sponsor
- Lead sponsor
- Romark Laboratories L.C.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
Conditions
- Enterovirus
- Rhinovirus
Interventions
NitazoxanideDrug
Nitazoxanide 600 mg administered orally twice daily for five days
PlaceboDrug
Placebo administered orally twice daily for five days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint)Time frame: Up to 21 days
Locations
45 sites in 2 countries. Site status is shown where the registry gives one.
Vanguard Study Site
Birmingham, Alabama
Vanguard Study Site
Birmingham, Alabama
Vanguard Study Site
Pelham, Alabama
Vanguard Study Site
Hot Springs, Arkansas
Vanguard Study Site
Anaheim, California
Vanguard Study Site
Westminster, California
Vanguard Study Site
Wilmington, California
Vanguard Study Site
Miami, Florida
Vanguard Study Site
Miami, Florida
Vanguard Study Site
Miami, Florida
Vanguard Study Site
Orlando, Florida
Vanguard Study Site
Tampa, Florida
Vanguard Study Site
Stockbridge, Georgia
Vanguard Study Site
Blackfoot, Idaho
Vanguard Study Site
Meridian, Idaho
Vanguard Study Site
Nampa, Idaho
Vanguard Study Site
Evanston, Illinois
Vanguard Study Site
Valparaiso, Indiana
Vanguard Study Site
Louisville, Kentucky
Vanguard Study Site
New Orleans, Louisiana
Vanguard Study Site
New Orleans, Louisiana
Vanguard Study Site
Baltimore, Maryland
Vanguard Study Site
St Louis, Missouri
Vanguard Study Site
Missoula, Montana
Vanguard Study Site
Bellevue, Nebraska
Vanguard Study Site
Las Vegas, Nevada
Vanguard Study Site
Brooklyn, New York
Vanguard Study Site
Raleigh, North Carolina
Vanguard Study Site
Cincinnati, Ohio
Vanguard Study Site
Cleveland, Ohio
Vanguard Study Site
Columbus, Ohio
Vanguard Study Site
Dayton, Ohio
Vanguard Study Site
Medford, Oregon
Vanguard Study Site
East Providence, Rhode Island
Vanguard Study Site
Jackson, Tennessee
Vanguard Study Site
Milan, Tennessee
Vanguard Study Site
Austin, Texas
Vanguard Study Site
Carrollton, Texas
Vanguard Study Site
Houston, Texas
Vanguard Study Site
McAllen, Texas
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.